Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Nutrition Reports

03-05-2024 | Pancreatic Cancer | REVIEW

Harnessing Plant Flavonoids to Fight Pancreatic Cancer

Authors: Chengu Niu, Jing Zhang, Patrick I. Okolo 3rd

Published in: Current Nutrition Reports

Login to get access

Abstract

Purpose of Review

This review draws on the last fifteen years (2009–2024) of published data to summarize the potential effect of plant flavonoids on pancreatic carcinogenesis and discuss the possible mechanisms of action to establish their applicability as anti-cancer agents.

Recent Findings

This review found that the plant flavonoids with anti-pancreatic cancer activity mainly include chalcones, dihydrochalcones, flavanols, flavanones, flavones, isoflavonoids, flavonols, isoflavones, and flavanonols. Most of these flavonoids have anti-proliferative, pro-apoptotic, cell cycle arrest, anti-angiogenic, anti-inflammatory, anti-epithelial-mesenchymal transition, and anti-metastatic properties. Some flavonoids can also regulate autophagy, immune and glucose uptake in the context of pancreatic cancer. Several molecules and signaling pathways are associated with the pharmacological activities of plant flavonoids, including AMP-activated protein kinase, mitogen-activated protein kinases, phosphatidylinositol-3-kinase/protein kinase B, nuclear factor-κB, signal transducer, and activator of transcription 3, Smad3, epidermal growth factor receptor, and vascular endothelial growth factor.

Summary

This review provides strong evidence that plant flavonoids have potential against pancreatic carcinogenesis in experimental animals through various pharmacological mechanisms. They are a promising resource for use as adjuvant anti-cancer therapy. However, randomized controlled clinical trials with those flavonoids are needed.
Literature
1.
Abboud Y, Samaan JS, Oh J, Jiang Y, Randhawa N, Lew D, et al. Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001–2018. Gastroenterology. 2023;164(6):978-89.e6.PubMedCrossRef
2.
3.
Amri F, Koulali H, Jabi R, Zazour A, Bouziane M, Ismaili Z, et al. Pancreatic cancer: experience from an emerging country in North Africa. J Cancer Res Clin Oncol. 2023;149(15):14297–302.PubMedCrossRef
4.
Masugi Y, Takamatsu M, Tanaka M, Hara K, Inoue Y, Hamada T, et al. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. J Pathol Clin Res. 2023;9(5):339–53.PubMedPubMedCentralCrossRef
5.
Springfeld C, Ferrone CR, Katz MHG, Philip PA, Hong TS, Hackert T, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol. 2023;20(5):318–37.PubMedCrossRef
6.
Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran CM, Rawcliffe C, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):157–68.PubMedCrossRef
7.
Mukhtar S, Moradi A, Kodali A, Okoye C, Klein D, Mohamoud, et al. On the Menu: Analyzing the Macronutrients, Micronutrients, Beverages, Dietary Patterns, and Pancreatic Cancer Risk. Cureus. 2023;15(9):e45259.PubMedPubMedCentral
8.
Mir SA, Dar A, Hamid L, Nisar N, Malik JA, Ali T, et al. Flavonoids as promising molecules in the cancer therapy: An insight. Curr Res Pharmacol Drug Discov. 2023;6:100167.PubMedPubMedCentralCrossRef
9.
Wang Y, Mou Y, Lu S, Xia Y, Cheng B. Polymethoxylated flavonoids in citrus fruits: absorption, metabolism, and anticancer mechanisms against breast cancer. PeerJ. 2024;12:e16711.PubMedPubMedCentralCrossRef
10.
Asgharian P, Tazehkand AP, Soofiyani SR, Hosseini K, Martorell M, Tarhriz V, et al. Quercetin Impact in Pancreatic Cancer: An Overview on Its Therapeutic Effects. Oxid Med Cell Longev. 2021;2021:4393266.PubMedPubMedCentralCrossRef
11.
Yuan D, Guo Y, Pu F, Yang C, Xiao X, Du H, et al. Opportunities and challenges in enhancing the bioavailability and bioactivity of dietary flavonoids: A novel delivery system perspective. Food Chem. 2024;430:137115.PubMedCrossRef
12.
Usman OH, Kumar S, Walker RR 3rd, Xie G, Sumajit HC, Jalil AR, et al. Differential modulation of cellular phenotype and drug sensitivity by extracellular matrix proteins in primary and metastatic pancreatic cancer cells. Mol Biol Cell. 2023;34(13):ar130.PubMedPubMedCentralCrossRef
13.
Cao J, Wu J, Yang P, Qian K, Cheng Y, Xu M, et al. Dual Enzyme Cascade-Activated Popcorn-Like Nanoparticles Efficiently Remodeled Stellate Cells to Alleviate Pancreatic Desmoplasia. ACS Nano. 2023;17(20):19793–809.PubMedCrossRef
14.
Roginsky AB, Ujiki MB, Ding XZ, Adrian TE. On the potential use of flavonoids in the treatment and prevention of pancreatic cancer. In Vivo. 2005;19(1):61–7.PubMed
15.
Zhang X, Chen J, Xi B, Liu Y, Wang S, Gu L, et al. Agrimoniin is a dual inhibitor of AKT and ERK pathways that inhibit pancreatic cancer cell proliferation. Phytother Res. 2023;37(9):4076–91.PubMedCrossRef
16.
Chen J, Liu F, Wu J, Yang Y, He J, Wu F, et al. Effect of STK3 on proliferation and apoptosis of pancreatic cancer cells via PI3K/AKT/mTOR pathway. Cell Signal. 2023;106:110642.PubMedCrossRef
17.
Zheng B, Zheng Y, Zhang N, Zhang Y, Zheng B. Rhoifolin from Plumula Nelumbinis exhibits anti-cancer effects in pancreatic cancer via AKT/JNK signaling pathways. Sci Rep. 2022;12(1):5654.PubMedPubMedCentralCrossRef
18.
Kwak MK, Yang KM, Park J, Lee S, Park Y, Hong E, et al. Galangin enhances TGF-β1-mediated growth inhibition by suppressing phosphorylation of threonine 179 residue in Smad3 linker region. Biochem Biophys Res Commun. 2017;494(3–4):706–13.PubMedCrossRef
19.
•• Ruan Q, Wen C, Jin G, Yuan Z, Yang X, Wen Z, et al. Phloretin-induced STAT3 inhibition suppresses pancreatic cancer growth and progression via enhancing Nrf2 activity. Phytomedicine. 2023;2023(118):154990. This article elucidates the anti-cancer role of phloretin in pancreatic cancer through inhibition of cell proliferation.
20.
Du J, Tang B, Wang J, Sui H, Jin X, Wang L, et al. Antiproliferative effect of alpinetin in BxPC-3 pancreatic cancer cells. Int J Mol Med. 2012;29(4):607–12.PubMedPubMedCentralCrossRef
21.
Vu HA, Beppu Y, Chi HT, Sasaki K, Yamamoto H, Xinh PT, et al. Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor. J Biomed Biotechnol. 2010;2010:290516.PubMedCrossRef
22.
Yao K, Chen H, Lee MH, Li H, Ma W, Peng C, et al. Licochalcone A, a natural inhibitor of c-Jun N-terminal kinase 1. Cancer Prev Res (Phila). 2014;7(1):139–49.PubMedCrossRef
23.
Yoshizawa M, Shiozaki A, Ashihara E. Depletion of DNTTIP2 induces cell cycle arrest in pancreatic cancer cells. Cancer Genomics Proteomics. 2024;21(1):18–29.PubMedPubMedCentralCrossRef
24.
• Su J, Wang L, Yin X, Zhao Z, Hou Y, Ye X, et al. Rottlerin exhibits anti-cancer effect through inactivation of S phase kinase-associated protein 2 in pancreatic cancer cells. Am J Cancer Res. 2016;6(10):2178–91. A mechanism by which rottlerin induces cell cycle arrest that constrain tumour growth of pancreatic cancer is demonstrated here.
25.
Zhang Z, Auyeung KK, Sze SC, Zhang S, Yung KK, Ko JK. The dual roles of calycosin in growth inhibition and metastatic progression during pancreatic cancer development: A “TGF-β paradox.” Phytomedicine. 2020;68:153177.PubMedCrossRef
26.
Rasam S, Lin Q, Shen S, Straubinger RM, Qu J. Highly reproducible quantitative proteomics analysis of pancreatic cancer cells reveals proteome-level effects of a novel combination drug therapy that induces cancer cell death via metabolic remodeling and activation of the extrinsic apoptosis pathway. J Proteome Res. 2023;22(12):3780–92.PubMedCrossRef
27.
Zhang T, Wang X, Zhang Q, Li K, Yang D, Zhang X, et al. Intrinsic and extrinsic pathways of apoptosis induced by multiple antibiotics residues and ocean acidification in hemocytes of scallop Argopecten irradians irradians: An interactionist perspective. Ecotoxicol Environ Saf. 2024;269:115806.PubMedCrossRef
28.
Khakinezhad Tehrani F, Ranji N, Kouhkan F, Hosseinzadeh S. PANC-1 cancer stem-like cell death with silybin encapsulated in polymersomes and deregulation of stemness-related miRNAs and their potential targets. Iran J Basic Med Sci. 2021;24(4):514–23.PubMedPubMedCentral
29.
Zhang Y, Li Z, Min Q, Palida A, Zhang Y, Tang R, et al. 8-Chrysoeriol, as a potential BCL-2 inhibitor triggers apoptosis of SW1990 pancreatic cancer cells. Bioorg Chem. 2018;77:478–84.PubMedCrossRef
30.
Du J, Jiang F, Xu SS, Huang ZF, Chen LL, Li L. Tephrosin induces apoptosis of human pancreatic cancer cells through the generation of reactive oxygen species. J Cancer. 2021;12(1):270–80.PubMedPubMedCentralCrossRef
31.
Lee HS, Kim SH, Kim BM, Safe S, Lee SO. Broussochalcone a is a novel inhibitor of the orphan nuclear receptor NR4A1 and induces apoptosis in pancreatic cancer cells. Molecules. 2021;26(8):2316.PubMedPubMedCentralCrossRef
32.
Kim C, Kim JH, Oh EY, Nam D, Lee SG, Lee J, et al. Blockage of STAT3 signaling pathway by morusin induces apoptosis and inhibits invasion in human pancreatic tumor cells. Pancreas. 2016;45(3):409–19.PubMedCrossRef
33.
Phillips PA, Sangwan V, Borja-Cacho D, Dudeja V, Vickers SM, Saluja AK. Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Cancer Lett. 2011;308(2):181–8.PubMedPubMedCentralCrossRef
34.
• Huo M, Xia A, Cheng W, Zhou M, Wang J, Shi T, et al. Rutin promotes pancreatic cancer cell apoptosis by upregulating miRNA-877–3p expression. Molecules. 2022;27(7):2293. This work impressively demonstrates rutin as novel apoptosis-inducing agent for the treatment of pancreatic cancer.
35.
Huang Q, Zhang J, Peng J, Zhang Y, Wang L, Wu J, et al. Effect of baicalin on proliferation and apoptosis in pancreatic cancer cells. Am J Transl Res. 2019;11(9):5645–54.PubMedPubMedCentral
36.
Huang H, Li X, Yu L, Liu L, Zhu H, Cao W, et al. Wogonoside inhibits TNF receptor-associated factor 6 (TRAF6) mediated-tumor microenvironment and prognosis of pancreatic cancer. Ann Transl Med. 2021;9(18):1460.PubMedPubMedCentralCrossRef
37.
Bhardwaj V, Tadinada SM, Jain A, Sehdev V, Daniels CK, Lai JC, et al. Biochanin A reduces pancreatic cancer survival and progression. Anticancer Drugs. 2014;25(3):296–302.PubMedCrossRef
38.
Li Y, Wang Y, Li L, Kong R, Pan S, Ji L, et al. Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-κB signaling pathway both in vitro and in vivo. Tumour Biol. 2016;37(6):7345–55.PubMedCrossRef
39.
Vargas JNS, Hamasaki M, Kawabata T, Youle RJ, Yoshimori T. The mechanisms and roles of selective autophagy in mammals. Nat Rev Mol Cell Biol. 2023;24(3):167–85.PubMedCrossRef
40.
Xu H, Tan M, Hou GQ, Sang YZ, Lin L, Gan XC, et al. Blockade of DDR1/PYK2/ERK signaling suggesting SH2 superbinder as a novel autophagy inhibitor for pancreatic cancer. Cell Death Dis. 2023;14(12):811.PubMedPubMedCentralCrossRef
41.
Yu L, Chen M, Zhang R, Xu T. Antitumor effects of glychionide-a flavonoid in human pancreatic carcinoma cells are mediated by activation of apoptotic and autophagic pathways, cell cycle arrest, and disruption of mitochondrial membrane potential. Med Sci Monit. 2019;25:962–9.PubMedPubMedCentralCrossRef
42.
•• Zhang Z, Chen WQ, Zhang SQ, Bai JX, Liu B, Yung KK, et al. Isoliquiritigenin inhibits pancreatic cancer progression through blockade of p38 MAPK-regulated autophagy. Phytomedicine. 2022;106:154406. This work defines a dominant role of autophagy in potential anti-pancreatic cancer effects of isoliquiritigenin.
43.
Li SJ, Sun SJ, Gao J, Sun FB. Wogonin induces Beclin-1/PI3K and reactive oxygen species-mediated autophagy in human pancreatic cancer cells. Oncol Lett. 2016;12(6):5059–67.PubMedPubMedCentralCrossRef
44.
Liu X, Peng X, Cen S, Yang C, Ma Z, Shi X. Wogonin induces ferroptosis in pancreatic cancer cells by inhibiting the Nrf2/GPX4 axis. Front Pharmacol. 2023;14:1129662.PubMedPubMedCentralCrossRef
45.
Jia S, Xu X, Zhou S, Chen Y, Ding G, Cao L. Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. Cell Death Dis. 2019;10(2):142.PubMedPubMedCentralCrossRef
46.
Huang C, Li H, Xu Y, Xu C, Sun H, Li Z, et al. BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Signal Transduct Target Ther. 2023;8(1):271.PubMedPubMedCentralCrossRef
47.
Ghalehbandi S, Yuzugulen J, Pranjol MZI, Pourgholami MH. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol. 2023;949:175586.PubMedCrossRef
48.
An YF, Pu N, Jia JB, Wang WQ, Liu L. Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions. Biochim Biophys Acta Rev Cancer. 2023;1878(5):188958.PubMedCrossRef
49.
He L, Wu Y, Lin L, Wang J, Wu Y, Chen Y, et al. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway. Cancer Sci. 2011;102(1):219–25.PubMedCrossRef
50.
• Saito K, Matsuo Y, Imafuji H, Okubo T, Maeda Y, Sato T, et al. Xanthohumol inhibits angiogenesis by suppressing nuclear factor-κB activation in pancreatic cancer. Cancer Sci. 2018;109(1):132–40. This is an elegant study demonstrating that xanthohumol as anti-angiogenesis agent exerts its anti-cancer effects in pancreatic cancer.
51.
Caronni N, La Terza F, Vittoria FM, Barbiera G, Mezzanzanica L, Cuzzola V, et al. IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer. Nature. 2023;623(7986):415–22.PubMedCrossRef
52.
Wu Y, Seufert I, Al-Shaheri FN, Kurilov R, Bauer AS, Manoochehri M, et al. DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma. Gut. 2023;72(12):2344–53.PubMedCrossRef
53.
Karamitopoulou E, Wenning AS, Acharjee A, Zlobec I, Aeschbacher P, Perren A, et al. Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer. Gut. 2023;72(8):1523–33.PubMedCrossRef
54.
Kürbitz C, Heise D, Redmer T, Goumas F, Arlt A, Lemke J, et al. Epicatechin gallate and catechin gallate are superior to epigallocatechin gallate in growth suppression and anti-inflammatory activities in pancreatic tumor cells. Cancer Sci. 2011;102(4):728–34.PubMedCrossRef
55.
Yousuf S, Qiu M, Voith von Voithenberg L, Hulkkonen J, Macinkovic I, Schulz AR, et al. Spatially resolved multi-omics single-cell analyses inform mechanisms of immune dysfunction in pancreatic cancer. Gastroenterology. 2023;165(4):891-908.e14.PubMedCrossRef
56.
Zhang S, Fang W, Zhou S, Zhu D, Chen R, Gao X, et al. Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis. Nat Commun. 2023;14(1):5123.PubMedPubMedCentralCrossRef
57.
Liu X, Zhang H, Cao J, Zhuo Y, Jin J, Gao Q, et al. Isobavachalcone activates antitumor immunity on orthotopic pancreatic cancer model: a screening and validation. Front Pharmacol. 2022;13:919035.PubMedPubMedCentralCrossRef
58.
Zheng X, Li D, Li J, Wang B, Zhang L, Yuan X, et al. Optimization of the process for purifying icariin from Herba Epimedii by macroporous resin and the regulatory role of icariin in the tumor immune microenvironment. Biomed Pharmacother. 2019;118:109275.PubMedCrossRef
59.
• Feng YB, Chen L, Chen FX, Yang Y, Chen GH, Zhou ZH, et al. Immunopotentiation effects of apigenin on NK cell proliferation and killing pancreatic cancer cells. Int J Immunopathol Pharmacol. 2023;37:3946320231161174.Feng and colleagues demonstrate apigenin-mediated immunopotentiation properties contribute to its anti-tumor effect for pancreatic cancer.
60.
Koch V, Weitzer N, Dos Santos DP, Gruenewald LD, Mahmoudi S, Martin SS, et al. Multiparametric detection and outcome prediction of pancreatic cancer involving dual-energy CT, diffusion-weighted MRI, and radiomics. Cancer Imaging. 2023;23(1):38.PubMedPubMedCentralCrossRef
61.
Song Q, Zhang K, Sun T, Xu C, Zhao W, Zhang Z. Knockout of ENO1 leads to metabolism reprogramming and tumor retardation in pancreatic cancer. Front Oncol. 2023;13:1119886.PubMedPubMedCentralCrossRef
62.
Hu X, Peng X, Zhang Y, Fan S, Liu X, Song Y, et al. Shikonin reverses cancer-associated fibroblast-induced gemcitabine resistance in pancreatic cancer cells by suppressing monocarboxylate transporter 4-mediated reverse Warburg effect. Phytomedicine. 2024;123:155214.PubMedCrossRef
63.
• Park TH, Kim HS. Eupatilin suppresses pancreatic cancer cells via glucose uptake inhibition, AMPK activation, and cell cycle arrest. Anticancer Res. 2022;42(1):483–91. This study showed inhibition of glucose uptake as the underlying mechanism mediating the eupatilin-induced cell cycle arrest in pancreatic cancer.
64.
Zhu H, Xiao Y, Guo H, Guo Y, Huang Y, Shan Y, et al. The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism. Aging (Albany NY). 2021;13(23):25089–105.PubMedCrossRef
65.
Ni F, Tang H, Wang C, Zhang H, Zheng C, Zhang N, et al. Baohuoside I inhibits the proliferation of pancreatic cancer cells via mTOR/S6K1-Caspases/Bcl2/Bax apoptotic signaling. Cancer Manag Res. 2019;11:10609–21.PubMedPubMedCentralCrossRef
66.
He RZ, Zheng JH, Yao HF, Xu DP, Yang MW, Liu DJ, et al. ADAMTS12 promotes migration and epithelial-mesenchymal transition and predicts poor prognosis for pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2023;22(2):169–78.PubMedCrossRef
67.
Chen Q, Guo H, Jiang H, Hu Z, Yang X, Yuan Z, et al. S100A2 induces epithelial-mesenchymal transition and metastasis in pancreatic cancer by coordinating transforming growth factor β signaling in SMAD4-dependent manner. Cell Death Discov. 2023;9(1):356.PubMedPubMedCentralCrossRef
68.
Ye T, Su J, Huang C, Yu D, Dai S, Huang X, et al. Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells. Onco Targets Ther. 2016;9:7481–92.PubMedPubMedCentralCrossRef
69.
• Lou C, Zhang F, Yang M, Zhao J, Zeng W, Fang X, et al. Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells. PLoS One. 2012;7(12):e50956. This paper shows that inhibition of EMT have important roles in the potential anti-pancreatic cancer effects of naringenin.
70.
Sadri A. Is target-based drug discovery efficient? discovery and “Off-Target” mechanisms of all drugs. J Med Chem. 2023;66(18):12651–77.PubMedCrossRef
71.
Mahmoud L, Cougnoux A, Bekiari C, Ruiz Araceli, de Castroviejo Teba P, El Marrahi A, Panneau G, et al. Microscopy-based phenotypic monitoring of MDA-MB-231 spheroids allows the evaluation of phenotype-directed therapy. Exp Cell Res. 2023;425(2):113527.PubMedCrossRef
72.
Magistrati M, Gilea AI, Gerra MC, Baruffini E, Dallabona C. Drug drop test: how to quickly identify potential therapeutic compounds for mitochondrial diseases using yeast saccharomyces cerevisiae. Int J Mol Sci. 2023;24(13):10696.PubMedPubMedCentralCrossRef
73.
Lu QY, Zhang L, Moro A, Chen MC, Harris DM, Eibl G, et al. Detection of baicalin metabolites baicalein and oroxylin-a in mouse pancreas and pancreatic xenografts. Pancreas. 2012;41(4):571–6.PubMedPubMedCentralCrossRef
74.
Nguyen MTT, Nguyen HX, Le TH, Do TNV, Dang PH, Pham TV, et al. A new flavanone derivative from the rhizomes of Boesenbergia pandurata. Nat Prod Res. 2022;36(8):1959–65.PubMedCrossRef
75.
Nöthlings U, Murphy SP, Wilkens LR, Boeing H, Schulze MB, Bueno-de-Mesquita HB, et al. A food pattern that is predictive of flavonol intake and risk of pancreatic cancer. Am J Clin Nutr. 2008;88(6):1653–62.PubMedCrossRef
76.
Gundogdu G, Dodurga Y, Cetin M, Secme M, Cicek B. The cytotoxic and genotoxic effects of daidzein on MIA PaCa-2 human pancreatic carcinoma cells and HT-29 human colon cancer cells. Drug Chem Toxicol. 2020;43(6):581–7.PubMedCrossRef
77.
Rossi M, Lugo A, Lagiou P, Zucchetto A, Polesel J, Serraino D, et al. Proanthocyanidins and other flavonoids in relation to pancreatic cancer: a case-control study in Italy. Ann Oncol. 2012;23(6):1488–93.PubMedCrossRef
78.
Wiedmann L, De Angelis RF, Vaquero-Siguero N, Donato E, Espinet E, Moll I, et al. HAPLN1 potentiates peritoneal metastasis in pancreatic cancer. Nat Commun. 2023;14(1):2353.PubMedPubMedCentralCrossRef
79.
Krauß L, Schneider C, Hessmann E, Saur D, Schneider G. Epigenetic control of pancreatic cancer metastasis. Cancer Metastasis Rev. 2023;42(4):1113–31.PubMedPubMedCentralCrossRef
80.
Hanin L. The circulation stage of the metastatic cascade: A mathematical description and its clinical implications. J Theor Biol. 2023;572:111582.PubMedCrossRef
81.
• Chua AW, Hay HS, Rajendran P, Shanmugam MK, Li F, Bist P, et al. Butein downregulates chemokine receptor CXCR4 expression and function through suppression of NF-κB activation in breast and pancreatic tumor cells. Biochem Pharmacol. 2010;80(10):1553–62. This seminal article reports that butein inhibits the migration and invasion of pancreatic cancer by targeting NF-κB signaling.
82.
Zheng W, Lu S, Cai H, Kang M, Qin W, Li C, et al. Deguelin inhibits proliferation and migration of human pancreatic cancer cells in vitro targeting hedgehog pathway. Oncol Lett. 2016;12(4):2761–5.PubMedPubMedCentralCrossRef
83.
Lee J, Lee J, Kim SJ, Kim JH. Quercetin-3-O-glucoside suppresses pancreatic cancer cell migration induced by tumor-deteriorated growth factors in vitro. Oncol Rep. 2016;35(4):2473–9.PubMedCrossRef
84.
Huang X, Dai S, Dai J, Xiao Y, Bai Y, Chen B, et al. Luteolin decreases invasiveness, deactivates STAT3 signaling, and reverses interleukin-6 induced epithelial-mesenchymal transition and matrix metalloproteinase secretion of pancreatic cancer cells. Onco Targets Ther. 2015;8:2989–3001.PubMedPubMedCentralCrossRef
85.
Lee J, Kim JH. Kaempferol inhibits pancreatic cancer cell growth and migration through the blockade of EGFR-related pathway in vitro. PLoS ONE. 2016;11(5):e0155264.PubMedPubMedCentralCrossRef
86.
Lewis A, Nagrial A. Systematic review of single-agent vs. multi-agent chemotherapy for advanced pancreatic adenocarcinoma in elderly vs. younger patients. Cancers (Basel). 2023;15(8):2289.
87.
Mangione W, Falls Z, Samudrala R. Effective holistic characterization of small molecule effects using heterogeneous biological networks. Front Pharmacol. 2023;14:1113007.PubMedPubMedCentralCrossRef
88.
Malhotra L, Kaur P, Ethayathulla AS. Flavonoids as potential reactivators of structural mutation p53Y220C by computational and cell-based studies. J Biomol Struct Dyn. 2023;29:1–12.CrossRef
89.
Ibanez V, Vaitkus K, Zhang X, Ramasamy J, Rivers AE, Saunthararajah Y, et al. Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF. Blood Adv. 2023;7(15):3891–902.PubMedPubMedCentralCrossRef
90.
•• Liu X, Yang F, Jia D, Dong X, Zhang Y, Wu Z. Case report: A case study on the treatment using icaritin soft capsules in combination with lenvatinib achieving impressive PR and stage reduction in unresectable locally progressive pancreatic cancer and a literature review. Front Genet. 2023;14:1167470. First clinical evidence of icaritin in combination with lenvatinib resulting in a significant downstaging of the patient’s pancreatic tumor.
91.
Lee J, Kim DH, Kim JH. Combined administration of naringenin and hesperetin with optimal ratio maximizes the anti-cancer effect in human pancreatic cancer via down regulation of FAK and p38 signaling pathway. Phytomedicine. 2019;58:152762.PubMedCrossRef
92.
Sun H, Zhang N, Jin Y, Xu H. Cardamonin promotes the apoptosis and chemotherapy sensitivity to gemcitabine of pancreatic cancer through modulating the FOXO3a-FOXM1 axis. Dose Response. 2021;19(4):15593258211042164.PubMedPubMedCentralCrossRef
93.
Lim HK, Kwon HJ, Lee GS, Moon JH, Jung J. Chrysin-induced G protein-coupled estrogen receptor activation suppresses pancreatic cancer. Int J Mol Sci. 2022;23(17):9673.PubMedPubMedCentralCrossRef
94.
Zhou L, Yang C, Zhong W, Wang Q, Zhang D, Zhang J, et al. Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells. Biochem Pharmacol. 2021;193:114813.PubMedCrossRef
95.
• Elbaz HA, Lee I, Antwih DA, Liu J, Hüttemann M, Zielske SP. Epicatechin stimulates mitochondrial activity and selectively sensitizes cancer cells to radiation. PLoS One. 2014;9(2):e88322. This paper suggests epicatechin as a potentiator for radiation responses in pancreatic cancer.
96.
Li Z, Zou X, Zhu H, Chen M, Zhao Y. Inhibitory effect of baicalein combined with gemcitabine in human pancreatic cancer cell lines. Oncol Lett. 2018;15(4):5459–64.PubMedPubMedCentral
97.
Suzuki R, Kang Y, Li X, Roife D, Zhang R, Fleming JB. Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells. Anticancer Res. 2014;34(9):4685–92.PubMedPubMedCentral
98.
• Liu ZJ, Xu W, Han J, Liu QY, Gao LF, Wang XH, et al. Quercetin induces apoptosis and enhances gemcitabine therapeutic efficacy against gemcitabine-resistant cancer cells. Anticancer Drugs. 2020;31(7):684–92. This study provides a mechanism by which quercetin in combination with gemcitabine resulted in increased potential anti-pancreatic cancer effects compared with gemcitabine alone.
99.
Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic cancer: a review of current treatment and novel therapies. J Invest Surg. 2023;36(1):2129884.PubMedCrossRef
Metadata
Title
Harnessing Plant Flavonoids to Fight Pancreatic Cancer
Authors
Chengu Niu
Jing Zhang
Patrick I. Okolo 3rd
Publication date
03-05-2024
Publisher
Springer US
Published in
Current Nutrition Reports
Electronic ISSN: 2161-3311
DOI
https://doi.org/10.1007/s13668-024-00545-9
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits